Operational revenue stood at Rs 2,414 million, while EBITDA rose by 35.7 per cent to Rs 497 million, with margins climbing to 20.6 per cent from 16.3 per cent in Q2 FY24
Read More_20240724175817_original_image_20.webp)
The profit after tax declined by 19 per cent year-on-year to Rs 76 crores
Read More
The company informed that its revenue reached Rs. 2,859 crores, reflecting a 10 per cent increase compared to the same period last year
Read More
Focusing sharply on its core business resulted in a 68 per cent compound annual growth rate (CAGR), reducing adjusted negative EBITDA from Rs 162 crore to Rs 17 crore
Read More
The company's mission focuses on reducing avoidable blindness in India by developing affordable and portable ophthalmic screening devices
Read More
For the annual performance in FY24, HCG's revenue was Rs 19,121 million
Read More
On an yearly basis, gross profit for FY24 was Rs16,291 million, up 22 per cent from Rs 13,328 million in FY23
Read More
In Q4 FY24, JB Pharma recorded a revenue of Rs 862 crores, marking a 13 per cent increase from Rs 762 crores in Q4 FY23
Read More
